C4 Therapeutics, Inc. (CCCC)

Over the past six months, C4 Therapeutics' stock price has been impacted by several events. The expansion of their partnership with Roche had a positive impact, while the first patient dosed in a Phase 1b trial of cemsidomide led to a stock increase. An inducement grant resulted in a stock decrease. The company reported its fourth quarter and full year 2025 financial results and participated in upcoming March conferences, which saw a stock increase. The stock experienced a drop, contributing to a year of losses, and C4 Therapeutics issued its earnings results, beating analysts' consensus estimates.

As a clinical-stage biopharmaceutical company, C4 Therapeutics' primary focus is on research, development, and clinical trials, making traditional demand seasonality not directly applicable. However, historical data indicates that December has been the strongest month for CCCC stock, while March tends to be the weakest month.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop small molecule medicines. They operate in the biotechnology industry, focusing on human therapeutics and utilize their TORPEDO® platform to design medicines for difficult-to-treat diseases. Their pipeline includes Cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphoma, CFT1946 for BRAF V600X mutant proteins, and CFT8919 for non-small cell lung cancer (NSCLC).

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. While its clinical trials indicate an international reach, the company's core corporate and operational base is in the United States.

C4 Therapeutics has a "Moderate Buy" consensus rating from analysts, with an average price target of $11.57. However, the company's reputation has been influenced by concerns about decreased G-CSF utilization, the Inflation Reduction Act, regulatory scrutiny, and recent insider trading activity. The company has been struggling with severely negative profitability margins.

The ownership of C4 Therapeutics (CCCC) stock is a mix of institutional, retail, and individual investors. Institutional investors own approximately 46.81% to 52.65% of the stock, while insiders own approximately 3.34%. Public companies and individual investors collectively own between 5.83% and 44.02% of the stock.